Thomas Castellano
Director of Finance/CFO chez ABZENA PLC
Fortune : 708 165 $ au 31/03/2024
Profil
Thomas P. Castellano est actuellement vice-président mondial chargé des finances opérationnelles chez Catalent, Inc. Il est également membre du conseil d'administration de Catalent France Beinheim SA. M. Castellano a obtenu un diplôme de premier cycle et un MBA à la Seton Hall University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CATALENT INC
0,01% | 04/12/2023 | 12 545 ( 0,01% ) | 708 165 $ | 31/03/2024 |
Postes actifs de Thomas Castellano
| Sociétés | Poste | Début |
|---|---|---|
| ABZENA PLC | Director of Finance/CFO | 05/06/2023 |
Catalent France Beinheim SA
 Catalent France Beinheim SA Pharmaceuticals: MajorHealth Technology Catalent France Beinheim SA is engaged in softgel development and manufacturing operations. It offers formulation development and manufacturing services for controlled substances, highly potent compounds, and hormones. The firm’s technologies include optiform® solution suite, optigel™ bio, and rp scherer softgel technology. The company was founded on May 3, 1965 and is headquartered in Beinheim, France. | Director/Board Member | - |
| Catalent Belgium Holding SA | Director/Board Member | 05/08/2021 |
Anciens postes connus de Thomas Castellano
| Sociétés | Poste | Fin |
|---|---|---|
| CATALENT, INC. | Director of Finance/CFO | 13/04/2023 |
Formation de Thomas Castellano
| Seton Hall University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CATALENT, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Catalent Belgium Holding SA | |
Catalent France Beinheim SA
Catalent France Beinheim SA Pharmaceuticals: MajorHealth Technology Catalent France Beinheim SA is engaged in softgel development and manufacturing operations. It offers formulation development and manufacturing services for controlled substances, highly potent compounds, and hormones. The firm’s technologies include optiform® solution suite, optigel™ bio, and rp scherer softgel technology. The company was founded on May 3, 1965 and is headquartered in Beinheim, France. | Health Technology |
Abzena Ltd.
 Abzena Ltd. BiotechnologyHealth Technology Abzena Ltd. engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It offers antibody discover and candidate screening, immunology and immunogenicity assessment, antibody and protein engineering, bio conjugation, custom synthesis of cytotoxic payloads, reagents, and other small molecules, manufacture of payload linkers, development of manufacturing cell lines, and manufacture of biopharmaceuticals. The company was founded by Sunil Shaunak in 2001 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
